Characterization of familial Waldenström's macroglobulinemia

Treon, Steven P.; Hunter, Zachary; Aggarwal, Abha; Ewen, E. P.; Masota, S.; Lee, C.; Santos, Daniel Ditzel; Hatjiharissi, Evdoxia; Liu, Xu; Leleu, Xavier; Tournilhac, Olivier; Patterson, Christopher J.; Manning, R.J.; Branagan, Andrew R.; Morton, Cynthia C.

doi:10.1093/annonc/mdj111

Cited by 164 publications

(99 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…8 A number of affected families presenting multiple cases, as well as case-control and cohort studies, have been published showing familial clustering of LPL and WM. [9][10][11][12][13] Recently, based on data from a referral clinic with particular focus on familial disease, Treon et al reported that 19% of their WM patients had at least one first-degree relative affected with WM or another B-cell disorder. 13 To quantify risk estimates for familial aggregation in the general population, we recently performed a large population-based study, including 2,144 LPL/WM patients, 8,279 population-based matched controls, and linkable first-degree relatives of patients (n=6,177) and controls (n=24,609).…”

Section: Lymphomasmentioning

confidence: 99%

“…[9][10][11][12][13] Recently, based on data from a referral clinic with particular focus on familial disease, Treon et al reported that 19% of their WM patients had at least one first-degree relative affected with WM or another B-cell disorder. 13 To quantify risk estimates for familial aggregation in the general population, we recently performed a large population-based study, including 2,144 LPL/WM patients, 8,279 population-based matched controls, and linkable first-degree relatives of patients (n=6,177) and controls (n=24,609). 14 We found first-degree relatives of LPL/WM patients had a significantly increased risk of developing LPL/WM, other subtypes of NHL (including CLL), and MGUS, compared to first-degree relatives of controls, with the highest risk for LPL/WM (Table 1).…”

Section: Lymphomasmentioning

confidence: 99%

See 1 more Smart Citation

Genetic and immune-related factors in the pathogenesis of lymphoproliferative and plasma cell malignancies

Kristinsson

Goldin²,

Björkholm³

et al. 2009

Haematologica

View full text Add to dashboard Cite

show abstract

Section: Lymphomasmentioning

confidence: 99%

Section: Lymphomasmentioning

confidence: 99%

Genetic and immune-related factors in the pathogenesis of lymphoproliferative and plasma cell malignancies

Kristinsson

Goldin²,

Björkholm³

et al. 2009

Haematologica

View full text Add to dashboard Cite

show abstract

“…[43][44][45][46] Some patients have cellular infiltration at the pulmonary parenchymal level, 47,48 being coughing the most common symptom, followed by dyspnea and chest pain. Renal infiltration has also been reported, 49 as well as cutaneous infiltration (maculopapular lesions, plaques or nodules) 7,50 and infiltration of periorbital structures, such as the tear gland and retro-orbital lymphoid tissue (ocular tremors). 51,52 The infiltration of malignant cells in the central nervous system is responsible for a rare neurological disorder called Bing-Neel syndrome.…”

Section: Clinical Symptomsmentioning

confidence: 99%

“…5 In relation to familial predisposition, an association is estimated in 20% of cases. 6,7 In first degree family relations there is a high risk of developing lymphoproliferative diseases, which is twenty times higher for WM/LPL. 8 pathophySIology It is believed that WM originates in memory B-lymphocytes.…”

mentioning

confidence: 99%

Waldenström's macroglobulinemia - a review

Coimbra

Neves

Lima

et al. 2014

Rev. Assoc. Med. Bras.

View full text Add to dashboard Cite

Waldenström's macroglobulinemia (WM) is a lymphoproliferative disease of B lymphocytes, characterized by a lymphoplasmocytic lymphoma in the bone marrow and by IgM monoclonal hypergammaglobulinemia. It was first described in 1944 by Jan Gösta Waldenström, reporting two patients with oronasal bleeding, lymphadenopathy, anemia, thrombocytopenia, high erythrocyte sedimentation rate and serum viscosity, normal radiography and bone marrow infiltrated by lymphoid cells. The WM is a rare disease with a typically indolent clinical course, affecting mainly individuals aged between 63 and 68 years. Most patients have clinical signs and symptoms related to hyperviscosity resulting from IgM monoclonal gammopathy, and/or cytopenias resulting from bone marrow infiltration by lymphoma. The differential diagnosis with other lymphomas is essential for the assessment of prognosis and therapeutic approach. Treatment of patients with asymptomatic WM does not improve the quality of life of patients, or increase their survival, being recommended, therefore, their follow-up. For the treatment of symptomatic patients, alkylating agents, purine analogs and anti-CD20 monoclonal antibodies are used. However, the disease is incurable and the response to therapy is not always favorable. Recent studies have shown promising results with bortezomib, an inhibitor of proteasomes, and some patients respond to thalidomide. In patients with relapse or refractory to therapy, autologous transplantation may be indicated. The aim of this paper is to describe in detail the current knowledge on the pathophysiology of WM, main clinical manifestations, diagnosis, prognosis and treatment.

show abstract

“…Waldenstro¨m's macroglobulinemia (WM) is a B-cell malignancy characterized by the underlying pathological diagnosis of lymphoplasmacytic lymphoma using REAL or WHO criteria and the presence of IgM monoclonal gammopathy [1]. While a familial predisposition may exist in up to 20% of patients with WM, a precipitating cause remains unknown for most patients [2].…”

Section: Introductionmentioning

confidence: 99%

Hepatitis C viral infection is not associated with Waldenström's macroglobulinemia

Leleu

O’Connor

et al. 2006

American J Hematol

View full text Add to dashboard Cite

While a familial predisposition may exist in up to 20% of patients with Waldenströ m's Macroglobulinemia (WM), the precipitating cause of this B-cell malignancy remains unknown in most patients. In previous studies, an association between hepatitis C virus (HCV) infection and WM has been suggested as etiological. This relationship has been the subject of debate, however, with some studies demonstrating increased incidence of HCV infection among WM patients and other studies showing no such association exists. This discordance might be attributable to the analytical method used, HCV antibody detection, which might be ineffective in patients with immunosuppression. We therefore analyzed the prevalence of HCV in a large population of WM patients utilizing both an HCV antibody detection immunoassay as well as qualitative polymerase chain reaction assay to directly detect HCV presence in serum samples. None of 100 randomly tested WM patients in this study tested positive for HCV by either analytical method. Our results therefore demonstrate a lack of association between HCV and WM. Am. J. Hematol. 82:83-84, 2007. V V C 2006 Wiley-Liss, Inc.

show abstract

Characterization of familial Waldenström's macroglobulinemia

Cited by 164 publications

References 31 publications

Genetic and immune-related factors in the pathogenesis of lymphoproliferative and plasma cell malignancies

Genetic and immune-related factors in the pathogenesis of lymphoproliferative and plasma cell malignancies

Waldenström's macroglobulinemia - a review

Hepatitis C viral infection is not associated with Waldenström's macroglobulinemia

Contact Info

Product

Resources

About